Introduction
Endothelin-1 (ET-1), the most potent vasoconstrictor known, was first described in 1988. 1 The endothelin family also includes endothelin-2, endothelin-3, and the sarafotoxins. The endothelins are widely distributed in tissues, produced by endothelial cells and many epithelial cell types. [2] [3] [4] [5] Under normal conditions, ET-1 apparently maintains vascular tone and exerts its action in a variety of tissues and organs. [4] [5] [6] [7] [8] [9] Recently, through other investigations of endothelin's pleiotropic actions, ET-1 has emerged as an important peptide in a host of biologic functions, including development, cellular proliferation, apoptosis, and cancer. [10] [11] [12] Endothelin-1 sequence is highly conservative among all mammalian species and most high vertebrates, emphasizing its central role in fundamental biologic processes. There are 2 endothelin receptors, endothelin receptor A (ET A ) and endothelin receptor B (ET B ), that have been identified in different mammalian tissues. They are 63% identical in amino acid sequence, but are encoded by distinct genes located in the chromosomes 4 (ET A ) and 13 (ET B ). [13] [14] [15] Endothelin receptors are distributed in a variety of cells and tissues in different proportions, suggesting potentially opposite regulatory functions. Endothelin receptor expression is up-regulated by ischemia, 16 cyclosporin, 17 and interleukin-1␤ (IL-1␤). 18 Production of endothelin or endothelin receptor knock-out mice allowed the evaluation of the role and biologic significance of different members of the endothelin family. ET-1 or ET A receptordeficient mice had abnormalities of craniofacial tissue derived from the first pharyngeal arch. Changes were incompatible with life, and mice died of respiratory failure at birth. 19 On the other hand, it appears that the ET B receptor is essential in the development of neural crest-derived cell lineages, and its deficiency produces pigmentary disorders and aganglionic megacolon, resembling human Hirschsprung disease. [20] [21] [22] Because of obvious ET-1 involvement in the vasoconstriction, a number of endothelin receptor antagonists have been developed to block ET-1 interaction with its receptors, both to study the specific results of ET-1 actions and for possible therapeutic use. 12, [23] [24] [25] One fundamental biologic process to which ET- 1 has not yet been definitely linked is the development of immune responses and particularly an immune function mediated by the most effective antigen-presenting cells, dendritic cells (DCs). First described in 1973, 26 these cells present as immature DCs in nonlymphoid tissue with the capacity to recognize, take up, and process antigen. After acquiring antigen, they migrate to lymph nodes and, as mature DCs, present the antigen to T cells, stimulating their proliferation and differentiation. Thus, as antigen-presenting cells, DCs play a crucial role in the development of specific immune responses, [27] [28] [29] and DC stimulation or suppression can effectively alter immune reactions.
ET-1 is produced by many cell types, including macrophages, 30 another type of antigen-presenting cell. ET-1 affects macrophage function, promoting tumor necrosis factor ␣ (TNF-␣) production through its action on the ET A receptor, 31 thus demonstrating proinflammatory function. However, there are currently no data on the relationship between ET-1 and DCs. Since ET-1 has almost ubiquitous presence in both lymphoid and nonlymphoid tissues, it is reasonable to hypothesize that it may affect DC function. The aim of this study was to examine if the endothelin axis (including ET-1 and both endothelin receptors) influences DC function, and through them, the immune response. We have demonstrated that DCs produce large amounts of ET-1 upon maturation, with concomitant up-regulation of both endothelin receptors. Functional studies showed that the modification of the endothelin axis has a profound effect on the development, function, and survival of mature DCs. To the best of our knowledge, this is the first demonstration that DCs produce ET-1, as well as express ET receptors, and that the endothelin axis can modify DC function, with a subsequent effect on immune response.
Materials and methods

Cells
DCs were generated from CD14 ϩ monocytes obtained from human peripheral blood of healthy volunteers, as described earlier. 32 After gradient separation on HistoPrep medium (1.077 g/mL; Sigma, St Louis, MO), adherent cells were isolated from peripheral blood mononuclear cells on plastic (37°C, one hour) and cultured in 6-well plates in complete medium, supplemented with 1000 U/mL recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and 1000 U/mL rhIL-4 (Cito G&M, Wexford, PA). Nonadherent DCs were harvested 7 to 8 days later and examined by flow cytometry. Cultured cells were CD14 Ϫ , CD3 Ϫ , CD20 Ϫ , HLA-DR ϩ , CD80 ϩ CD86 ϩ CD40 ϩ and CD1a ϩ , and CD83 ϩ , suggesting a common phenotype of monocyte-derived DCs. DC maturation was induced either by TNF-␣ [33] [34] [35] (50 ng/mL; Cito G&M) or inactivated Staphylococcus aureus (S aureus, 5 L/mL; Sigma) for 48 hours. 36, 37 ET-1 (American Peptide, Sunnyvale, CA), ET A receptor antagonists ABT-627 (Abbott Labs, Chicago, IL) and BQ-123 (American Peptide), and ET B receptor antagonist A-192621 (Abbott Labs) were added to DCs at a final concentration of 10 Ϫ7 M during the last 48 hours of culture.
ET-1 ELISA
The ET-1 enzyme-linked immunosorbent assay (ELISA) system (BIOTRAK; Amersham Biosciences, Piscataway, NJ) was used for determination of ET-1 concentrations in cell-free supernatants. In every assay, samples and standards were run in duplicates and read at 450-nm wavelength on a Benchmark microplate reader (Bio-Rad Labs, Hercules, CA). ET-1 concentrations were normalized based on cell counts and determined by computer software-generated interpolation from the standard curve.
Immunohistochemistry
DCs were harvested and placed on microscope slides using a Cytospin centrifuge (Shandon Lipshaw, Pittsburgh, PA). Samples were air-dried overnight and fixed in ice-cold acetone. Slides were washed in phosphatebuffered saline (PBS) and incubated for one hour at room temperature with the ET A or ET B antibodies (Abbott Labs) at a dilution of 1:250. Further staining with secondary antibodies and development was performed using Vectastatin ABC system (Vector Labs, Burlingame, CA), following the manufacturer's recommendations. Negative controls included staining with irrelevant isotype-matched antibodies. Semiquantitative assessment of slides was performed by 2 authors (G.G. and M.R.S.) independently to evaluate the intensity of staining.
Radioreceptor assay
DCs were grown in 6-well plates and collected on day 7. Cells were centrifuged at 200g for 7 minutes. Pellets were resuspended in 20 mL "cold" buffer (50 mM Tris [tris(hydroxymethyl)aminomethane]-HCl, 1 g/mL pepstatin, and 1 g/mL leupeptin; pH 7.7 at 4°C) and homogenized. Resulting suspensions were centrifuged at 60 000g for 30 minutes at 4°C. Pellets were resuspended in "warm" buffer (50 mM Tris-HCl, 1 g/mL pepstatin, 1 g/mL leupeptin; pH 7.7 at 37°C), kept at 37°C for 40 minutes, and then centrifuged at 60 000g for 30 minutes at 20°C. Pellets were kept at Ϫ80°C until used. To define the dissociation constant (K d ) and the binding maximum (Bmax), duplicate aliquots (2 ϫ 125 L) of membrane suspensions were incubated with increasing concentrations (0.98 to 500 nM) of nonradioactive ET-1, and corresponding 125 I-ET-1 (2000 Ci/mmol [74 Tbq/mmol]; Amersham Biosciences) was added with increasing concentrations (3.9 to 2000 pM) as well. For the competitive binding studies, membrane suspensions were incubated with increasing concentrations (0 to 5 M) of nonradioactive ET-1, ABT-627 and A-192621, and a fixed concentration (100 pM) of 125 I-ET-1. Incubation was carried out for 2 hours on ice. Next, membrane suspensions were pipetted onto 25-mm diameter glass microfiber filters (GM/C filters; Whatman, Kent, United Kingdom) under the vacuum suction, and filters were washed with 10 mL cold (4°C) Hanks buffered saline solution. Filters were placed in the 5-mL vials, and the radioactivity was determined on Wallac 1470 gamma counter (PerkinElmer Life Sciences, Turku, Finland). Obtained results (in cpm) were converted to femtomole per milligram of protein using web-based radioactivity calculator software from GraphPad (San Diego, CA).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Cells were lysed using RNA-Bee (1 mL per 5 ϫ 10 6 cells), and the total RNA was extracted as per the manufacturer's (Tel-Test, Friendswood, TX) recommendations. The amount of RNA was determined by a spectrophotometric reading at 260 nm. Synthesis of cDNA from 3 g total RNA was carried out using Superscript Preamplification System (GIBCO BRL, Grand Island, NY) with oligo(dT) primers. Amplification of cDNA was performed with 35 cycles of PCR in a 50-L mixture with Taq DNA Polymerase (GeneChoice, Frederick, MD) and primers at a final concentration of 0.2 M. To confirm the quality of cDNA for PCR in every case, human ␤-actin was coamplified using ␤-actin cDNA primers (5Ј-CCCAGGCACCAGGGCGTGAT and 5Ј-TCAAACATGATCTGGGT-CAT, 262-bp product). For endothelin receptors, the following primers were used: forward, 5Ј-CACTGGTTGGATGTGTAATC and reverse, 5Ј-GGAGATCAATGACCACATAG, for human ET A receptor (366-bp PCR product); forward, 5Ј-TCAACACGGTTGTGTCCTGC and reverse, 5Ј-ACTGAATAGCCACCAATCTT, for human ET B receptor (530-bp PCR product). 38 Each reaction cycle consisted of 1 minute at 93°C (denaturation), 1 minute at 56°C (annealing), and 2 minutes at 72°C (extension). Products of PCR were electrophoresed on 1.2% agarose gel and stained with ethidium bromide (Bio-Rad Labs) for visualization on Molecular Imager FX (Bio-Rad Labs). Obtained PCR products were sequenced using ABI model 3100 Automated DNA Sequencers by the University of Pittsburgh sequencing facility to confirm the specificity.
Gene microarray
For gene array analyses, DCs were obtained from 2 healthy volunteers and divided into 4 groups: unstimulated DCs, DCs stimulated with S aureus during the last 48 hours of culture, and DCs stimulated with S aureus and treated either with ABT-627 or A-192621 (ET A and ET B receptor antagonists, respectively) for the last 48 hours of culture. DCs were collected and snap frozen. Affymetrix chip analysis (Santa Clara, CA) was performed as described earlier. 39 Briefly, total RNA was extracted from DCs using Trizol and Qiagen RNeasy kit (Qiagen, Valencia, CA), following the manufacturer's recommendations. Total RNA (approximately 8 g) was used for the synthesis of first-strand cDNA with Gibco BRL Superscript II system and T7-(dT) 24 primer (5Ј-GGCCAGTGAATTGTAATACGACTCACTATA-GGGAGGCGC-(dT) 24 -3Ј). The second-strand cDNA synthesis was carried out at 16°C by adding Escherichia coli (E coli) DNA ligase, E coli DNA polymerase I, and RnaseH in the reaction. The cDNA was purified through phenol/chloroform and ethanol precipitation. Double-stranded DNA was then converted into cRNA using in vitro transcription (IVT) and biotinylated nucleotides with the MEGAscript system (Ambion, Austin, TX) according to the manufacturer's recommendations.
The IVT product was cleaned using Qiagen RNeasy columns, and 15 g cRNA was fragmented at 95°C for 35 minutes. The fragmented cRNA was hybridized with pre-equilibrated Affymetrix chips at 45°C for 14 to 16 hours (human genome U133A set was used, containing more than 22 000 genes and expression sequence tags). The hybridizations were then washed and stained with streptavidin-phycoerythrin (SAPE) according to the manufacturer's (Affymetrix) recommendation. The hybridized gene chips were scanned using Agilent ChipScanner (Affymetrix) to detect hybridization signals.
For analysis, hybridization data from text files were imported to a Microsoft Excel spreadsheet (Seattle, WA). To determine gene products with a significant increase of expression, we analyzed all data sets for at least 3-fold increase in signal intensity. Obtained data were normalized using the ratio of signal intensity derived from GAPDH (glyceraldehydes-3-phosphate dehydrogenase) in comparing sets. The level of significance was set at a probability of .05.
Mixed leukocyte reaction
Allogeneic CD3 ϩ T cells were generated using human T-cell enrichment columns (R&D Systems, Minneapolis, MN). Isolated T cells were placed in the round-bottom 96-well plates, 3 ϫ 10 5 cells per well. DCs were stimulated either with TNF-␣ or S aureus, and treated with either ET-1, ABT-627, A-192621, or BQ-123 for 48 hours. DCs were then washed, resuspended in complete medium, counted using trypan blue, and added to T cells at different ratios in triplicates. The starting number of live (trypan blue negative) DCs was the same in each group. After 72 hours of incubation at 37°C, radioactive thymidine ( 3 H-TdR; New England Nuclear, Boston, MA) was added to the DC/T-cell mixture, 1 Ci (0.037 MBq) per well. T-cell proliferation was measured by the 3 H-TdR incorporation in 16 hours. Cells were harvested onto GF/C glass fiber filter paper with a semiautomated microharvester, and 3 H-TdR incorporation was determined by liquid scintillation spectroscopy and expressed as cpm.
IL-12 ELISA
DuoSet ELISA development kit calibrated for human IL-12 p70 (R&D Systems) was used to determine IL-12 concentration in DC supernatants, according to the manufacturer's recommendations. DCs were counted using trypan blue before the experiment and supernatants were collected. Samples and standards were run as duplicates in every assay, and were read at 450 nm wavelength in reference to 540 nm. IL-12 concentrations were determined by computer software-generated interpolation from the standard curve and normalized based on cell counts (per million live cells).
Assessment of apoptosis
Annexin V assay. DCs were collected and double stained with fluorescein isothiocyanate-conjugated Annexin V (PharMingen, San Diego, CA) and propidium iodide (Sigma). Annexin V was added according to the manufacturer's recommendations. Propidium iodide was used at a final concentration of 10 g/mL. Samples were analyzed by the FACScan flow cytometer with LYSYS II software package (Becton Dickinson, San Jose, CA).
Cell death ELISA. DCs were collected on day 8, after the 48-hour treatment with dexamethasone (10 Ϫ6 M) and with or without ET receptor inhibitors, and counted. Samples (30 000 cells) were assayed for death using an ELISA kit according to the manufacturer's specifications (Roche Diagnostics, Indianapolis, IN). This kit uses monoclonal antibodies directed against DNA and histones in a quantitative sandwich-enzyme-based format. The amount of histone-associated DNA fragments in the cell lysates was determined by a spectrophotometric reading at 405-nm wavelength. Untreated cells were used as controls.
Statistical analysis
For a single comparison of 2 groups the Student t test was used (SigmaStat Statistical Software; SPSS, Chicago, IL). If data distribution was not normal, Mann-Whitney rank sum test was used. For all analysis, the level of significance was set at a probability of .05 to be considered significant. Data are presented as the mean Ϯ standard error of the mean (SEM). All experiments were repeated at least 3 times.
Results
ET-1 production by human DCs
In the immature state, DCs secreted little or no ET-1, as was determined by ELISA (Figure 1) . Following the stimulation with either TNF-␣ or S aureus for 48 hours, ET-1 production by DCs increased significantly (Figure 1) . ET-1 concentration in the culture medium from immature DCs was 15.3 Ϯ 6.3 pg/mL per 10 6 cells, whereas TNF-␣-induced DC maturation resulted in a 10-fold increase in ET-1 levels in culture supernatants (170.5 Ϯ 36.9 pg/mL per 10 6 cells, P ϭ .004). Similarly, ET-1 concentrations increased 36-fold (559.9 Ϯ 172.3 pg/mL per 10 6 cells, P ϭ .006) when DCs were stimulated with S aureus.
Expression of endothelin receptors on human DCs
On unstimulated DCs, expression of the endothelin receptors ET A and ET B was also low, whereas stimulated DCs displayed a large increase in ET A and ET B expression ( Figure 2 ) as was assessed by immunostaining using specific ET A and ET B receptor antibodies. We performed semiquantitative evaluation of the slides. The staining of unstimulated DCs was graded as ϩ/ϩ with both ET A and ET B staining, whereas the staining of stimulated DCs was graded as ϩϩϩ/ϩϩϩ for ET A receptors and ϩϩ/ϩϩϩ for ET B receptors. These findings were confirmed by radioreceptor assay using 125 I-ET-1 ( Figure 3) . During saturation studies, receptor density on mature DCs was more than 2.5-fold higher than on immature DCs: Bmax was 760.3 Ϯ 162.6 fmol/mg protein versus 285.8 Ϯ 86.5 fmol/mg protein, respectively (P ϭ .02), whereas binding affinity was the same on mature and immature DCs (K d was 1.81 Ϯ 0.6 nM versus 1.78 Ϯ 0.9 nM, respectively). Competitive binding assays with ABT-627, a highly selective ET A receptor antagonist, and A-192621, a highly selective ET B receptor antagonist, were carried out to determine relative density of each receptor. Expression of messenger RNA for ET A and ET B receptors was confirmed as well in both mature and immature DCs by sequence analysis of RT-PCR amplified cDNA products against the published sequences for those receptor subtypes. Furthermore, the results of gene arrays also confirmed up-regulation of mRNA for ET-1, ET A , and ET B receptors (Table 1) 
Regulation of DC ability to activate T cells by ET receptor antagonists
The functional consequence of DC maturation is commonly measured by their ability to stimulate T-cell proliferation in a mixed leukocyte reaction (MLR) assay. 29 In MLRs ( Figure 5A ), as expected, mature DCs induced a significantly higher level of T-cell For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From proliferation compared with immature DCs. ET A receptor blockade on mature DCs with either ABT-627 or BQ-123 resulted in a statistically significant reduction of their ability to induce T-cell proliferation (P Ͻ .05 at DC-T-cell ratios ranging from 1:2187 to 1:9), whereas ET B receptor blockade on DCs with A-192621 had no effect on antigen-presenting capacity of DCs. The addition of exogenous ET-1 to mature DCs had no significant effect on MLR results, since mature DCs produce high levels of ET-1 by themselves ( Figure 1) . Similarly, ET-1 or endothelin receptor antagonists did not change antigen-presenting activity of immature DCs.
Effect of ET-1 on IL-12 production by DCs
Production of the IL-12 by DCs has an important regulatory function on the host immune response, particularly by regulating T helper 1 (Th1)/Th2 balance. Treatment of mature DCs with ET A receptor antagonist ABT-627 significantly reduced S aureusinduced IL-12 production from 584.8 Ϯ 152.2 pmol/mL per 10 6 cells to 179.8 Ϯ 77.4 pmol/mL per 10 6 cells (P Ͻ .05) ( Figure 5B ). However, neither exogenous ET-1 nor ET B receptor antagonist A-192621 had any significant effect on the induction of IL-12 secretion by mature DCs.
Modulation of DC survival by endothelin axis
In many cell types, ET-1 is both a mitogenic and an antiapoptotic factor primarily binding to the ET A receptor. Using either dexamethasone (10 Ϫ6 M) or serum starvation to induce apoptosis in DCs, we have shown that blockade of ET A receptors by ABT-627 or BQ-123 resulted in increased levels of DC apoptosis, as measured by both Annexin V binding (P Ͻ .05) and the cell death ELISA assay (P ϭ .002) ( Figure 6A and 6B, respectively) . Interestingly, blockade of ET B receptors on DCs with A-192621 led to an increased resistance of DCs to the dexamethasone-induced apoptosis, assessed by Annexin V binding assay (P ϭ .002) and cell death ELISA (P Ͻ .001).
Regulation of gene expression in DCs by endothelin axis
We have analyzed gene expression in DCs using human genome U133A set from Affymetrix. Tables 1, 3 , and 4. As shown, blocking of ET A receptors on DCs led to the increased expression of many proapoptotic genes, including genes for several caspases. In addition, down-regulation of the genes involved in the generation of type I immune response (interferon, IL-12, major histocompatibility complex [MHC] class II molecules) was also seen after ET A receptor blockade on DCs. In contrast, ET B receptor blockade on DCs was associated with the down-regulation of proapoptotic genes, for instance, serinethreonine kinase 17␣, bcl2-like protein 11, and others. Thus, the analysis of gene expression on DCs confirmed our data demonstrating the *Statistically significant difference. In the case of CD40, between human DCs and hDCs ϩ SA (P ϭ .012); CD80, between human DCs and hDCs ϩ SA (P ϭ .015); CD83, between human DCs and hDCs ϩ SA (P ϭ .003), between hDCs ϩ SA and hDCs ϩ SA ϩ ABT-627 (P Ͻ .001), and between hDCs ϩ SA and hDCs ϩ SA ϩ A-192621 (P ϭ .014); CD86, between human DCs and hDCs ϩ SA (P Ͻ .001); and HLA-DR, between human DCs and hDCs ϩ SA (P ϭ .004). 
Discussion
After being discovered as a potent vasoconstrictor, ET-1 was later demonstrated to possess a wide range of pleiotropic functions as well. 11, 12, 25, 40 This includes the regulation of basic cell functions such as cell survival, proliferation, and matrix remodeling. Endothelin-1 action is mediated by the ET A and ET B receptors. [13] [14] [15] While so-called "positive" ET-1 actions (vasoconstriction, improved survival, mitogenic action) are mediated primarily through the ET A receptors, the activation of the ET B receptors counteracts these activities in many cases, such as inducing vasodilation through nitric oxide (NO) release. 41 We have shown here that DCs produce large amounts of ET-1 after stimulation with either TNF-␣ or inactivated S aureus, with concomitant increase in the expression of ET A and ET B receptors. The range of ET-1 production by DCs after their stimulation with S aureus is wide, but the coefficients of variation (standard deviation/mean) were similar in both stimulated groups (0.53 for TNF-␣ and 0.62 for S aureus), indicating that variability is consistent across treatments. The wide ET-1 concentration range with S aureus treatment may be explained by the nonspecificity of its action and individual response of DCs derived from different For personal use only. on April 20, 2017 . by guest www.bloodjournal.org From volunteers. The mechanisms of ET-1 production from DCs upon stimulation will be the subject of future studies. Addition of an exogenous ET-1 to immature or mature DC cultures had no significant effect on DC function. Immature DCs express low levels of endothelin receptors, apparently insufficient to significantly impact their function following the ET-1 binding. On the other hand, mature DCs had high numbers of endothelin receptors and appear to be sufficiently stimulated with the DC-derived endogenous ET-1, explaining why the addition of exogenous ET-1 to DC culture did not significantly change DC phenotype or function. The large increase in both ligand (ET-1) and receptor (ET A , ET B ) expression occurring with DC maturation indicates the potential for a functional autocrine loop: DCs produce abundant ET-1 that binds to greater numbers of endothelin receptors. Blockade of the endothelin receptors had a profound effect on mature DCs. We observed a significant decline in the expression of CD83 with the blockade of ET A receptors. It is known that CD83 is the marker of mature DCs and that CD83 ϩ cells are the most effective stimulators in allogeneic MLRs. 42 Recent studies also demonstrated that CD83 is not just a DC marker, but probably has immunostimulatory as well as regulatory effects, 43 and it is possible that decreased expression of CD83 by itself might affect DC function. We have observed some changes in the expression of other costimulatory molecules as well (Table 2) . Although these differences were not statistically significant, they might have induced biologic effects. In addition, it is possible that proapoptotic features of the ET A receptor antagonists have contributed to the observed effects as well.
Another DC function affected by ET A receptor blockade was IL-12 production. IL-12 increases proliferation and activity of natural killer and T cells, and plays a central role in promoting type 1 T helper cell (TH1) responses. Its production by antigenpresenting cells seems to be essential for host defense against intracellular microbial infections and control of malignancy, [44] [45] [46] [47] and alterations in its production may affect the competence of the immune system. Our data demonstrated significant decrease in the IL-12 production by mature DCs with the blockade of the ET A receptor, suggesting the involvement of the ET-1/ET A loop in the generation of TH1 responses.
ET-1 is a known survival factor for many cell types, acting mainly through the ET A receptor. 1, 11, 38, 40, 48, 49 We observed a decreased resistance of mature DCs to apoptotic stimuli (high-dose dexamethasone or serum starvation) when ET A receptor was blocked, meaning that ET A receptor activation is protective and antiapoptotic in DCs. The role of the ET B receptor so far is not well studied. In general, it is believed that ET B receptor activation leads to cell differentiation and apoptosis, 50 but in some cell types ET B was found to promote cell survival. 51, 52 In our experiments, ET B receptor blockade in the presence of agonist (endogenous ET-1) resulted in increased resistance of DCs to apoptotic stimuli. Thus, ET B receptor activation on DCs seems to promote their apoptosis, and might play an important role in abolishing the specific immune responses.
Based on the loss of function associated with the administration of ET A receptor antagonists, it appears that ET A receptor stimulation improves DC survival, and mediates antigen-presenting T-cellstimulating and IL-12-producing features of DCs. These alterations in DCs are consistent with an immunostimulating role of ET A . These findings were further supported by gene array studies, demonstrating the up-regulation of proapoptotic genes associated with the ET A receptor blockade and down-regulation of proinflammatory cytokines (Table 3) . Gene array data obviously need to be confirmed with additional experiments, but changes in the expression levels of several genes in pathways involving apoptotic and immunostimulatory factors warrant further studies.
We have shown here that the blockade of ET B receptors improved survival and increased CD83 expression on DCs. It seems that observed ET B -mediated effects on DCs are the opposite of those mediated by the ET A receptor. This pattern of cell regulation was also seen in other endothelin-driven functions. The results of gene array experiments also demonstrated decreased expression of several proapoptotic genes (Table  4) in DCs after the blockade of ET B receptors. These divergent effects of ET-1 on DC function provide 2 means for potential immunomodulation, depending on receptor subtype targeted: blocking of ET A receptors may be immunosuppressive, whereas blocking of ET B receptors may be stimulatory for DCs.
The exact mechanisms of ET-1 action on DCs still need to be elucidated. Although the outcome of some experiments may be thought to be the result of increased DC apoptosis due to ET A receptor blockade (for example, CD83 expression), in most cases experiments were performed with the same number of live cells (MLR), or results have been normalized according to the number of counted live cells (IL-12 production). Still, due to apparent enhanced apoptosis of DCs with ET A receptor blockade, this possibility needs to be always kept in mind, with some monitoring of the number of live DCs before the start of experiment.
Another possible mechanism of ET influence on DCs worth exploring is the involvement of NO. As we have mentioned, ET B receptor activation was found to increase NO synthesis in endothelial cells. 41 Other studies also demonstrated the change in NO level with the stimulation or blockade of different ET receptors, with ET A receptor activation or ET B receptor blockade leading mostly to the decreased NO levels, 53, 54 while ET B receptor stimulation was accompanied with increased NO synthesis. 55 NO was also found to interfere with the ET-1/ET A -mediated increased cell proliferation. 56 Regarding DCs, it is known that NO may be involved in DC apoptosis 57, 58 and may have a role in DC-mediated T-cell proliferation. 59, 60 Further experiments should clarify the role of NO in ET-1-induced DC modifications.
Administration of ET A receptor antagonist in rats during the experimental renal transplantation improved graft survival, 61, 62 which was mainly attributed to the probable vasodilating features of the ET A receptor antagonists. It is possible, however, that improved graft survival was due to the ET A receptor blockade on DCs, accompanied by the suppression of their T-cell-stimulating capacity. In other studies, administration of BQ-123, an ET A receptor antagonist, inhibited eosinophil and mononuclear cell migration, due to the inhibition of CD4 ϩ and CD8 ϩ T lymphocytes. 63 We failed to identify endothelin receptors on T cells by immunohistochemical staining (data not shown), leading us to speculate that the inhibition of T cells might be mediated by DC suppression due to blockade of ET A receptors. However, this hypothesis requires further experimental confirmation.
In conclusion, our data showed for the first time that human DCs produce ET-1 and express functional ET A and ET B receptors, which are up-regulated during DC maturation. We demonstrated that ET-1 production and ET A activation play an important role in the activity of human DCs. The observed ability of ET A receptor antagonists to interfere with the behavior of DCs and suppression of DC-mediated immune response should be further explored, both experimentally and clinically, including many areas of possible DC-based therapies, ranging from cancer to transplantation. [64] [65] [66] [67] [68] [69] Likewise, the counter-regulatory activities of ET-1/ET B and ET-1/ ET A autocrine or paracrine loops might provide a new means to modulate DC function, such as increase in cell survival, cytokine production, and T-cell activation. The wide availability of selective ET receptor antagonists should accelerate these investigations.
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